Phillip Frost Paid for 30000 shares of Opko Health Inc. (NYSE:OPK) in an Insider Trading

Share with your friends










Submit

Phillip Frost Paid for 30000 shares of Opko Health in an Insider Trading-Transactions

Phillip Frost Insider Buy Transaction

A well-grounded and judicious move was made by the CEO & Chairman of Opko Health Inc. (NYSE:OPK) , Mr. Phillip Frost, on 20-11-2015, when he obtained a significant amount of company shares – 30,000, totalling $321,819 U.S Dollars , based on an avg price of $10.7 per every share. It seems he is very active lately as in the last 30 days, he bought additional 185,000 shares of the company, worth $1.80 million USD. Because it was a huge one trade, it’s not likely to remain a secret one. Phillip Frost today owns 181.27 million shares or 34.40 % of the company’s market cap.

Opko Health Inc Stock Rating, Sentiment and Fundamentals

Such a big acquisition lends credence to Mr. Phillip’s own optimism concerning the future of Opko Health Inc, and of its valuation. According to the six specialist analysts that are covering the -listed Opko Health Inc’s fundamentals, there is an expectation of earnings for each share of $-0.09 for the 2015 year, which gives Opko Health Inc a price to earnings ratio of NaN.

Rating & Sentiment
PsychSignal Social:SELL
Analysts Rating:BUY
Hedge Funds Sentiment:BUY
Stock Fundamentals
Earnings + FCF Trend:SELL
Sector/Industry Macro:BULLISH
Valuation Models:-
Technical Analysis
ST Trend:UP
MT Trend:DOWN
LT Trend:DOWN
OctaFinance Rating*:BUY

* Read How Our Stock Ratings System Works

Opko Health Inc’s share price has risen 7.83 % in the last 50 days and it’s today in strong and smooth bullish uptrend. We wonder what magic he is exactly using at the Florida-based company. We rate Opko Health Inc’s stock as buy not only because of the insider stock trade by Phillip but also in accordance with OctaFinance’s backtested stocks time-momentum model which is displayed below. Phillip Frost’s current net worth could surge by $1.27 billion USD if the stock price touches a medium-term trend target of $18.10. What about your own trading account?

Price Chart of Opko Health NYSE:OPK Stock

Phillip Frost Paid for 30000 shares of Opko Health in an Insider Trading-Stock-Price-Chart

Source: RightEdgeSystems, Yahoo Split & Dividend Adjusted Data and OctaFinance Interpretations

Hedge Funds Ownership

Review of SEC 13F filings disclose that 203 hedge funds and institutional investors have shares in Opko Health Inc. The tracked institutional investors have historically had a very high interest in Opko Health Inc’s stock, and that was also the case in Q2 2015. The institutional ownership was 15.21 % of the stock’s outstanding shares. Its up 7.55 % from Q1 2015. These institutional and hedge funds increased the total shares they own by 5.82 million to 82.87 million this quarter. A total of 52 funds opened new positions in Opko Health Inc and 72 increased their holdings. There were 32 funds that closed their positions and 47 that reduced them.

In all 203 of them, four hold the stock in Top 10. Some of these are: Oracle Investment Management Inc, Catalyst Capital Advisors Llc, Mivtachim The Workers Social Insurance Fund Ltd. (Under Special Management), Seven Eight Capital Llc.

HEDGE-FUNDS-LIST-DATABASE-FREE

Eagle Global Advisors Llc had the greatest investment with ownership of 14,000 shares as of Q2 2015 for 0.01% of the fund’s portfolio. Hollencrest Securities Llc is another bullish institutional manager possessing 45,827 shares of the company or 0.11% of their stocks portfolio. The stock is also 0.06% of the fund’s AUM. The New York-based fund Pinnacle Associates Ltd have 0.01% of their stock portfolio invested in the company’s market cap for 17,000 shares. In addition, The Georgia-based fund Ronald Blue & Co Llc disclosed it had purchased a stake worth 0.01% of the fund’s stock portfolio in the company. The Connecticut-based fund Oracle Investment Management Inc was also a notable believer in the company, with ownership of 4.96 million shares. Opko Health Inc is 9.68% of the fund’s stock portfolio.

Opko Health NYSE:OPK Company Profile

OPKO Health, Inc. (OPKO) is a biopharmaceutical and diagnostics company. The Company is involved in developing a range of solutions to diagnose, treat and prevent various conditions, including point-of-care tests, laboratory developed tests (LDTs), molecular diagnostics tests, and pharmaceuticals and vaccines. It operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment consists of two operating segments pharmaceutical research and development segment and pharmaceutical operations. Its diagnostics segment consists of pathology operations and point-of-care and molecular diagnostics operations. It owns pharmaceutical operations in Chile, Spain, Mexico, Israel, Uruguay and Brazil. The product pipeline includes several pharmaceutical compounds and technologies in research and development for a range of indications and conditions.

Company Website: Opko Health

Now its market value is: $5.86 billion and it has 526.98 million shares outstanding. Currently the company has 21.24% shareholders and the institutional ownership stands at 21.24%. Opko Health Inc has 674 employees. Opko Health Inc was founded in Delaware on 1991-11-18. The stock closed at $10.88 yesterday and it had average 2 days volume of 812816 shares. It is down from the 30 days average shares volume of 1335567. Opko Health Inc has a 250 days low of $8.11 and a 52w high of $19.20. The current price is below the 200 days SMA. Opko Health Inc last issued its quarterly earnings report on 11/09/2015. The company reported 0.25 EPS for the quarter, above the consensus estimate of -0.01 by 0.26. The company had a revenue of 143.03 million for 9/30/2015 and 42.43 million for 6/30/2015. Therefore, the revenue was 100.61 million up.

Phillip Frost is also Chief Executive Officer of Ivax Corp, director of Sevion Therapeutics, Inc., Ladenburg Thalmann Financial Services Inc, Cocrystal Pharma, Inc., Castle Brands Inc, Transenterix Inc., Prolor Biotech, Inc., Continucare Corp, Ideation Acquisition Corp., Northrop Grumman Corp /De/, Erba Diagnostics, Inc., 10 percent owner of Idi, Inc., Tiger X Medical, Inc., Vector Group Ltd, Vaporin, Inc., Passport Potash Inc, Chromadex Corp., Non Invasive Monitoring Systems Inc /Fl/, Winston Pharmaceuticals, Inc., Protalix Biotherapeutics, Inc., Glenrose Instruments Inc.

* The securities are held by Frost Gamma Investments Trust – of which Phillip Frost M.D. – is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma – Inc. – and the sole shareholder of Frost Gamma – Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities – except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

* These securities are owned directly by The Frost Group – LLC. Frost Gamma Investments Trust is a principal member of The Frost Group – LLC. The reporting person disclaims beneficial ownership of these securities – except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Opko Health - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.